Stat : Canadian Drug Price Board Member Resigns Over Government Failure Вђto Support Real Changeвђ™ - Mr Validity May 2026
In February 2023, , a member of Canada’s Patented Medicine Prices Review Board (PMPRB) , resigned in a blistering letter to the federal government. Herder , a health law expert at Dalhousie University , accused the Liberal government of failing to support "real change" and undermining the regulator's independence to favor the pharmaceutical industry. Key Reasons for Resignation
Herder’s resignation was followed shortly by the resignation of PMPRB Executive Director , signaling a leadership crisis at the agency. This turmoil occurred after a decade-long effort to modernize pricing rules in Canada, where drug prices remain among the highest in the world , second only to the U.S. and Switzerland. Resignations at Canada's drug pricing panel raise ... - PMC In February 2023, , a member of Canada’s
Herder’s departure was prompted by what he described as the government’s "unwillingness to support real change" in drug pricing reform. His specific grievances included: This turmoil occurred after a decade-long effort to
: He criticized then-Health Minister Jean-Yves Duclos for intervening on behalf of the pharmaceutical industry by asking the board to suspend consultations on new pricing guidelines. - PMC Herder’s departure was prompted by what